Q1 Earnings Forecast for RVPH Issued By Roth Capital

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Analysts at Roth Capital issued their Q1 2026 earnings estimates for shares of Reviva Pharmaceuticals in a research note issued to investors on Friday, April 4th. Roth Capital analyst B. Pachaiyappan forecasts that the company will post earnings per share of ($0.16) for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Roth Capital also issued estimates for Reviva Pharmaceuticals’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.19) EPS.

A number of other equities analysts have also weighed in on the company. Roth Mkm started coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 target price on the stock. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, January 10th. HC Wainwright decreased their price target on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, D. Boral Capital cut their target price on shares of Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.00.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $0.53 on Monday. The company has a market cap of $17.72 million, a price-to-earnings ratio of -0.48 and a beta of 0.05. Reviva Pharmaceuticals has a one year low of $0.49 and a one year high of $4.28. The firm has a fifty day moving average price of $1.33 and a two-hundred day moving average price of $1.44.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at about $25,000. Cornerstone Select Advisors LLC bought a new position in Reviva Pharmaceuticals during the 4th quarter valued at approximately $32,000. Drive Wealth Management LLC purchased a new stake in Reviva Pharmaceuticals in the 4th quarter worth approximately $36,000. XTX Topco Ltd bought a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth approximately $45,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Reviva Pharmaceuticals by 848.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after buying an additional 23,953 shares during the period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.